GLP-1 Weight Loss

What Are GLP-1 Receptor Agonists?

GLP-1 stands for glucagon-like peptide-1, a hormone your small intestine naturally releases after you eat. Its job is to signal your pancreas to produce insulin, tell your brain you’re full, and slow the rate at which food leaves your stomach. In people who struggle with obesity or metabolic disease, this signal is often weaker or shorter-lived than it should be. GLP-1 receptor agonist medications are designed to mimic and extend that signal — sometimes for days at a time — giving the body a sustained biological push toward better blood sugar control and meaningful weight loss.

These medications have changed the landscape of obesity medicine more than any development in the past two decades. At Scale Solutions, physician-led by Dr. Donald L. Gates, MD, GLP-1 therapy is one of the primary tools we use to help patients in Savannah, Pooler, and Hinesville, GA achieve lasting results that diets alone rarely deliver.

How GLP-1 Medications Work in the Body

Understanding the mechanism helps patients set realistic expectations and stick with treatment through the early adjustment period.

Brain Signaling: The Appetite Pathway

GLP-1 receptors are found in the hypothalamus — the brain region that governs hunger. When activated, they reduce appetite and food-seeking behavior. Patients often describe this as “food just stops being on my mind as much.” That reduced mental preoccupation with food is one of the most clinically significant and underreported benefits of these medications.

Gastric Emptying: Slowing the System Down

GLP-1 agonists delay the rate at which the stomach empties into the small intestine. This slowed digestion leads to earlier and more prolonged feelings of fullness after smaller meals. It also blunts post-meal blood sugar spikes — a critical benefit for patients with prediabetes or type 2 diabetes.

Insulin Secretion: Glucose-Dependent

Unlike older diabetes medications, GLP-1 agonists stimulate insulin release only when blood glucose is elevated — a property called “glucose-dependent” action. This dramatically reduces the risk of hypoglycemia (dangerously low blood sugar), making these medications much safer than older injectable agents.

Glucagon Suppression

Glucagon is the hormone that tells your liver to release stored sugar. GLP-1 medications suppress glucagon when it isn’t needed, helping keep blood sugar steady between meals.

The Cumulative Effect

When these four pathways work together — reduced appetite, slower gastric emptying, better insulin response, and controlled glucagon — the result is a sustained caloric deficit that doesn’t require the extreme willpower that traditional diets demand. The body’s own biology is working with you rather than against you.

Approved GLP-1 Medications We Prescribe

At Scale Solutions, we prescribe FDA-approved medications. Here is a brief overview of the three most relevant drugs in this class for weight management.

Semaglutide (Ozempic®, Wegovy®)

Semaglutide is a once-weekly subcutaneous injection. Ozempic® is FDA-approved for type 2 diabetes management; Wegovy® carries FDA approval specifically for chronic weight management in adults with a BMI of 30 or higher (or 27+ with a weight-related condition). Clinical trials in the STEP program demonstrated average weight loss of approximately 15% of body weight over 68 weeks when combined with lifestyle intervention. Learn more about semaglutide at Scale Solutions.

Tirzepatide (Mounjaro®, Zepbound®)

Tirzepatide is a dual GIP/GLP-1 receptor agonist — it activates two hormone pathways instead of one. Mounjaro® is approved for type 2 diabetes; Zepbound® is approved for weight management. The SURMOUNT-1 trial showed average weight loss of approximately 21% of body weight, making it the most effective weight-loss medication currently available. Learn more about tirzepatide at Scale Solutions.

Liraglutide (Saxenda®)

Liraglutide is a daily injection approved for chronic weight management. It was the first GLP-1 agonist to receive dedicated weight-management approval (2014). While its efficacy is somewhat lower than semaglutide or tirzepatide, it remains an option for patients who cannot tolerate or access the newer weekly agents. Average weight loss in clinical trials was approximately 5–8% of body weight.

Who Qualifies for GLP-1 Therapy?

FDA-approved indications for GLP-1 weight management medications generally include:

• Adults with a BMI of 30 kg/m² or higher (obesity)
• Adults with a BMI of 27–29.9 kg/m² plus at least one weight-related comorbidity — including type 2 diabetes, hypertension, high cholesterol, obstructive sleep apnea, or cardiovascular disease

Beyond BMI, Dr. Gates considers the full clinical picture: metabolic lab values, medication history, existing conditions, family history, and patient goals. Not every patient who qualifies on paper is the right candidate for every drug. Our intake process at all three locations — Savannah, Pooler, and Hinesville — includes a thorough physician evaluation before any prescription is written.

Who Should Not Use GLP-1 Agonists

These medications are contraindicated or require careful risk-benefit discussion in patients with:

• Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) — a black-box warning on the FDA label
• History of pancreatitis
• Severe gastrointestinal disease (e.g., gastroparesis)
• Pregnancy or active plans for pregnancy (discontinuation is recommended)
• Known hypersensitivity to the active ingredient

What the Research Says: Effectiveness Data

GLP-1 agonists are among the most studied drug classes in modern medicine. Here are the headline findings:

To put these numbers in perspective: a person weighing 250 pounds could expect to lose 37 to 52 pounds on semaglutide, or up to 52 pounds on tirzepatide, assuming consistent adherence and a supportive lifestyle program. These results represent a meaningful shift in metabolic health — not just cosmetic change.

Critically, a 2023 cardiovascular outcomes trial (SELECT) demonstrated that semaglutide reduced major adverse cardiovascular events by 20% in adults with obesity and established cardiovascular disease. This moved GLP-1 therapy from a metabolic drug to a cardiovascular risk reduction tool — a significant clinical milestone.

Side Effects and Safety Considerations

Common Side Effects

Most side effects with GLP-1 agonists are gastrointestinal and tend to be most pronounced during dose escalation. They typically diminish over the first 4–8 weeks:

• Nausea — the most frequently reported side effect, especially in weeks 1–4
• Vomiting — less common; often linked to eating too quickly or too large a meal
• Diarrhea or constipation — bowel habits can change; adequate hydration helps
• Fatigue — often transient and resolves within a few weeks
• Decreased appetite — technically a side effect, but also a therapeutic goal

Less Common but Important Risks

• Pancreatitis — rare; patients with a history of pancreatitis should discuss risk carefully with Dr. Gates
• Gallbladder disease — rapid weight loss of any cause (including GLP-1 use) can increase gallstone formation
• Thyroid C-cell tumors — observed in rodent studies at supratherapeutic doses; the clinical relevance in humans is not established, but the black-box warning requires disclosure
• Muscle loss — GLP-1s reduce fat mass but can also reduce lean mass if protein intake and resistance exercise are neglected. We counsel patients on this proactively.

Drug Interactions

GLP-1 agonists slow gastric emptying, which can affect the absorption of oral medications. Patients on thyroid medication, oral contraceptives, or blood pressure medications should review their full medication list with Dr. Gates at intake.

How Scale Solutions Prescribes GLP-1 Therapy

We do not write prescriptions on the first phone call or after a five-minute online questionnaire. Our approach reflects the physician-led, medically responsible standard we have maintained since Dr. Gates began practicing bariatric medicine in 1999.

Step 1: In-Person Physician Evaluation

Every patient meets with Dr. Gates personally. We review your weight history, diet history, previous weight-loss attempts, comorbidities, current medications, and your goals. This is not a checkbox exercise — it is a real clinical conversation.

Step 2: Lab Work

Before prescribing, we run a metabolic panel that typically includes: fasting glucose, HbA1c, lipid panel, comprehensive metabolic panel, thyroid function (TSH), and a complete blood count. These labs give us a baseline and screen for contraindications. They also help us track your progress at follow-up visits.

Step 3: Structured Dose Escalation

We start every patient at the lowest approved dose and escalate slowly — prioritizing tolerability. Rushing the titration schedule is one of the most common reasons patients drop out due to side effects. Slow and steady produces better outcomes.

Step 4: Ongoing Monitoring

We schedule follow-up appointments at 4 weeks, 8 weeks, and quarterly thereafter. We track weight, side effects, lab values, and metabolic markers. If something isn’t working — or if a side effect is interfering with quality of life — we adjust the plan.

Nutritional Support

Medication is one part of the program. We also provide B12 and lipotropic shots that support energy and liver function during active weight loss, along with dietary guidance emphasizing protein intake and hydration.

Cost and Insurance Overview

GLP-1 medications vary significantly in cost depending on whether you are using brand-name products through insurance or self-pay. Brand-name Wegovy® has a retail price above $1,000 per month, though many major insurance plans cover it with prior authorization for qualifying patients. Georgia Medicaid currently does not cover GLP-1 medications for weight loss unless the patient has a concurrent type 2 diabetes diagnosis.

For self-pay patients, Scale Solutions offers transparent pricing without surprise fees. We encourage patients to review our full pricing page and come to their initial consultation with questions about what options fit their situation.

Medicare Part D coverage for weight-loss medications is expanding. Beginning in 2026, CMS has announced a pathway to cover obesity pharmacotherapy through Medicare — details are still being finalized as of the time of this writing.

Frequently Asked Questions About GLP-1 Therapy

How quickly will I lose weight on a GLP-1 medication?

Most patients see some scale movement within the first 2–4 weeks, though the first few weeks are primarily about dose titration and tolerability. Significant weight loss — 5% or more of body weight — typically becomes apparent by weeks 8–12. Maximal effect is reached at 12–18 months of continued therapy.

Do I have to take GLP-1 medications forever?

Obesity is a chronic condition, and the research is clear that most patients regain weight when GLP-1 medication is stopped. This is not a character flaw — it reflects the biology of weight regain (ghrelin and leptin rebound). Some patients ultimately transition to lower maintenance doses or other strategies; that conversation is individualized and ongoing.

Can I use GLP-1 medication if I’m not diabetic?

Yes. FDA approvals for Wegovy® and Zepbound® are specifically for weight management and do not require a diabetes diagnosis. The eligibility criteria are BMI-based, as described above.

Is it safe to combine GLP-1 medications with lipotropic injections?

We use B12 and lipotropic injections as a complement to GLP-1 therapy in many patients. They serve different physiological purposes and are not contraindicated together. Dr. Gates reviews each patient’s complete plan individually.

What happens if I experience severe nausea?

Call our office. Do not stop the medication without speaking to Dr. Gates first. In most cases, nausea can be managed by slowing the titration schedule, adjusting meal timing, or making specific dietary modifications. Anti-nausea strategies are part of our patient education program.

Are compounded GLP-1 medications an option?

As of early 2025, the FDA removed semaglutide and tirzepatide from its drug shortage list, which has significantly restricted the legal compounding of these drugs at scale. We will discuss current availability and your options during your consultation.

Ready to learn whether GLP-1 therapy is right for you? Find a Scale Solutions location near you or call us at (912) 352-7546 to schedule an evaluation with Dr. Gates.

This page is for informational purposes only and is not medical advice. Consult Dr. Gates or another qualified clinician before starting any treatment.